Treprostinil (Orenitram) vs Treprostinil (Tyvaso)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Pulmonary Arterial Hypertension
Shared mechanism: IP receptor (prostacyclin pathway) · full Pulmonary Arterial Hypertension pipeline
Treprostinil (Orenitram)
Marketed by United Therapeutics
NCT00325403 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial with 349 participants enrolled and 228 included in the prespecified primary analysis. The clinical primary endpoint was met: oral treprostinil produced a statistically significant placebo-corrected improvement in six-minute walk distance at Week 12.
Reported efficacy
Six Minute Walk Distance (6MWD) (Baseline and Week 12): Six Minute Walk Distance (6MWD) (Baseline and Week 12): UT-15C (Oral Treprostinil) — 6MWD at Baseline: 350 meters (IQR 283 to 386); 6MWD at Week 12: 370 meters (IQR 300 to 418); Change in 6MWD from Baseline to Week 12: 25 meters (IQR -16 to 63) vs Placebo — 6MWD at Baseline: 339 meters (IQR 282 to 381); 6MWD at Week 12: 343 meters (IQR 246 to 403); Change in 6MWD from Baseline to Week 12: -5 meters (IQR -41 to 49) (met)
Result source: NCT00325403
Treprostinil (Tyvaso)
Marketed by United Therapeutics
NCT00147199 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial of 235 participants, with 115 receiving inhaled treprostinil and 120 receiving placebo. The prespecified clinical primary endpoint—change in peak 6-minute walk distance at Week 12—was met, with a between-group estimate of 20.0 meters (95% CI 8.0–32.8; p=0.00044).
Next expected readout: December 2027 · NCT07177703 (registry estimate)
Reported efficacy
Peak 6-minute Walk Distance (12 weeks): Peak 6-minute Walk Distance (12 weeks): Inhaled Treprostinil — Week 12: 366 meters (IQR 300 to 423); Change from Baseline: 21.6 meters (IQR -8 to 54) vs Placebo — Week 12: 360 meters (IQR 296 to 414.9); Change from Baseline: 3 meters (IQR -26 to 31.5) (met)
Result source: NCT00147199
Results for Pulmonary Arterial Hypertension
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
Coverage. Treprostinil (Orenitram): 5 of 5 rows · Treprostinil (Tyvaso): 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Treprostinil (Orenitram) | Treprostinil (Tyvaso) |
|---|---|---|
| 6MWD - Change absolute change · m No placebo or comparator arm | 2.7 m @ 24wka,b,c,d NCT02276872 · Phase 2 · registry result, not featured evidence show 2 more doses22.1 m @ 24wk NCT02276872 · Phase 2 · registry result, not featured evidence 12.8 m @ 24wk NCT02276872 · Phase 2 · registry result, not featured evidence · combination | 20 m @ 12wkb,c,d NCT01268553 · Phase 4 · registry result, not featured evidence 1 other source trial230 m @ 12wk NCT00705133 · Phase 2 · registry result, not featured evidence |
| Dropout rate | 21.9%e NCT00325403 · Phase 3 · Hypertension, Pulmonary Arterial Hypertension · phase 3 show 7 more results42.1% NCT01560637 · Phase 3 · registry result, not featured evidence 76.7% NCT01027949 · Phase 3 · registry result, not featured evidence 57.2% NCT01560624 · Phase 3 · registry result, not featured evidence 12.1% NCT00325442 · Phase 3 · registry result, not featured evidence 10%Cohort 1 (Transitioning From Paren NCT02276872 · Phase 2 · registry result, not featured evidence 0%Cohort 2 (Transitioning From Inhal NCT02276872 · Phase 2 · registry result, not featured evidence 0%Cohort 3 (Add-on to Current PAH Th NCT02276872 · Phase 2 · registry result, not featured evidence · combination | 11.3%f NCT00147199 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3 show 3 more results0% NCT01268553 · Phase 4 · registry result, not featured evidence 11% NCT00741819 · Phase 4 · registry result, not featured evidence 0% NCT00705133 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —e NCT00325403 · Phase 3 · Hypertension, Pulmonary Arterial Hypertension · phase 3 show 7 more results13.4% NCT01560637 · Phase 3 · registry result, not featured evidence 19.2% NCT01027949 · Phase 3 · registry result, not featured evidence — NCT01560624 · Phase 3 · registry result, not featured evidence — NCT00325442 · Phase 3 · registry result, not featured evidence 10%Cohort 1 (Transitioning From Paren NCT02276872 · Phase 2 · registry result, not featured evidence 0%Cohort 2 (Transitioning From Inhal NCT02276872 · Phase 2 · registry result, not featured evidence 0%Cohort 3 (Add-on to Current PAH Th NCT02276872 · Phase 2 · registry result, not featured evidence · combination | —f NCT00147199 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3 show 3 more results— NCT01268553 · Phase 4 · registry result, not featured evidence 4.1% NCT00741819 · Phase 4 · registry result, not featured evidence — NCT00705133 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 17.9%e NCT00325403 · Phase 3 · Hypertension, Pulmonary Arterial Hypertension · phase 3 show 7 more results43.8% NCT01560637 · Phase 3 · registry result, not featured evidence 61.2% NCT01027949 · Phase 3 · registry result, not featured evidence 33.5% NCT01560624 · Phase 3 · registry result, not featured evidence 18.4% NCT00325442 · Phase 3 · registry result, not featured evidence 50%Cohort 1 (Transitioning From Paren NCT02276872 · Phase 2 · registry result, not featured evidence 0%Cohort 2 (Transitioning From Inhal NCT02276872 · Phase 2 · registry result, not featured evidence 33.3%Cohort 3 (Add-on to Current PAH Th NCT02276872 · Phase 2 · registry result, not featured evidence · combination | 7.8%f NCT00147199 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3 show 3 more results0% NCT01268553 · Phase 4 · registry result, not featured evidence 13.7% NCT00741819 · Phase 4 · registry result, not featured evidence 0% NCT00705133 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | e headache 62.9% (placebo 19.5%) diarrhea 30.5% (placebo 15.6%) nausea 29.8% (placebo 18.2%) NCT00325403 · Phase 3 · Hypertension, Pulmonary Arterial Hypertension · phase 3 show 7 more resultsheadache 69.8% diarrhoea 66.2% flushing 42.8% NCT01560637 · Phase 3 · registry result, not featured evidence headache 78.1% diarrhoea 66.2% nausea 56.5% NCT01027949 · Phase 3 · registry result, not featured evidence headache 74.9% (placebo 34.9%) diarrhoea 69.4% (placebo 28.5%) flushing 44.5% (placebo 7.8%) NCT01560624 · Phase 3 · registry result, not featured evidence headache 86.2% (placebo 36.9%) nausea 64.4% (placebo 34.1%) diarrhea 60.9% (placebo 27.3%) NCT00325442 · Phase 3 · registry result, not featured evidence headache 100% diarrhoea 75% nausea 75% NCT02276872 · Phase 2 · registry result, not featured evidence · combination | f cough 53.9% (placebo 29.2%) headache 40.9% (placebo 22.5%) nausea 19.1% (placebo 10.8%) NCT00147199 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3 show 2 more resultsgeneral prostacyclin adverse reaction profile 100% NCT00705133 · Phase 2 · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bTrial phases differ: Phase 4 versus Phase 2.
- cPopulation context differs: registered conditions differ.
- dAssessment timepoints differ: 12 weeks versus 24 weeks.
- ePopulation comparability has not been reviewed for 7 of these studies.
- fPopulation comparability has not been reviewed for 3 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Treprostinil (Orenitram)
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 3 more results
+ 17 further endpoints in the CSV export.
Treprostinil (Tyvaso)
show 1 more result
+ 2 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Treprostinil (Orenitram)'s landscape · Treprostinil (Tyvaso)'s landscape